AtriCure (ATRC) Common Equity (2010 - 2026)

AtriCure (ATRC) has 17 years of Common Equity data on file, last reported at $491.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $491.7 million, up 8.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $491.7 million (up 8.15% YoY), and the FY2025 annual result was $491.9 million, up 6.72% from the prior year.
• Common Equity was little changed at $491.7 million in Q1 2026 per ATRC's latest filing, from $491.9 million in the prior quarter.
• Over five years, Common Equity peaked at $491.9 million in Q4 2025 and troughed at $450.3 million in Q3 2022.
• A 5-year average of $464.5 million and a median of $462.4 million in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 18.6% in 2022 and fell as far as 7.81% in 2022.
• A 5-year view of Common Equity shows it stood at $456.8 million in 2022, then rose by 2.06% to $466.2 million in 2023, then decreased by 1.12% to $461.0 million in 2024, then gained by 6.72% to $491.9 million in 2025, then retreated by 0.05% to $491.7 million in 2026.
• Business Quant data shows ATRC's Common Equity at $491.7 million in Q1 2026, $491.9 million in Q4 2025, and $476.5 million in Q3 2025.